We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 19.39 | 2.07% | 957.00 | 954.85 | 990.00 | 958.13 | 926.94 | 926.94 | 547,374 | 05:00:06 |
From May 2023 to May 2024
By Stephen Nakrosis
Ultragenyx Pharmaceutical said Evkeeza was approved by Health Canada to help treat certain patients with high cholesterol.
Evkeeza was discovered and developed by Regeneron Pharmaceuticals, which solely commercializes the product in the U.S., Ultragenyx said, adding it is responsible for commercialization efforts in countries outside of the U.S.
Evkeeza, or evinacumab, was approved as an adjunct to diet and other therapies to treat adult and pediatric patients five and older who suffer from homozygous familial hypercholesterolemia.
The U.S. National Institutes of Health said the rare life-threatening condition can cause "elevated circulating levels of low-density lipoprotein cholesterol and accelerated, premature atherosclerotic cardiovascular disease."
The treatment will be commercially available in Canada as of Nov. 25, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 25, 2023 17:57 ET (21:57 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
